Showing results (3981-3990 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|January 4, 2012
Nutraceuticals and Prevention of Neurodegeneration Herbal Medicines for the Prevention and Treatment of Alzheimer's DiseaseHyo Geun Kim, Myung Sook OhCurrent Pharmaceutical Design|January 26, 2012
Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammationCristina MullerCurrent Pharmaceutical Design|January 14, 2012
The ultra high risk approach to define psychosis riskAlison R Yung, Paolo Fusar-Poli, Barnaby NelsonCurrent Pharmaceutical Design|January 14, 2012
Basic symptoms and the prediction of first-episode psychosisFrauke Schultze-Lutter, Stephan Ruhrmann, Paolo Fusar-Poli, et al.Current Pharmaceutical Design|January 14, 2012
Can we detect psychotic-like experiences in the general population?B Nelson, P Fusar-Poli, A R YungCurrent Pharmaceutical Design|January 14, 2012
Neuroimaging and resilience factors--staging of the at-risk mental state?Renata Smieskova, Paolo Fusar-Poli, Anita Riecher-Rössler, et al.Current Pharmaceutical Design|January 14, 2012
Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72Andrea Mechelli, Paolo Fusar-Poli, Diana Prata, et al.Current Pharmaceutical Design|January 14, 2012
Immigration, social environment and onset of psychotic disordersFrançois Bourque, Elsje van der Ven, Paolo Fusar-Poli, et al.Current Pharmaceutical Design|January 14, 2012
Economic impact of early detection and early intervention of psychosisLucia R Valmaggia, Philip K McGuire, Paolo Fusar-Poli, et al.Current Pharmaceutical Design|February 1, 2012
Natural animal models of neurodegenerative protein misfolding diseasesInes Moreno-Gonzalez, Claudio SotoPageof 1,008